Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Erratum: Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab

Bibliographic Details
Main Author:	Frontiers Production Office
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Pharmacology
Subjects:	anlotinib non-small cell lung cancer (NSCLC) bevacizumab efficacy safety
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1092147/full

Similar Items

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
by: Fenge Jiang, et al.
Published: (2022-09-01)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
by: Zhujun Liu, et al.
Published: (2022-05-01)

The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study
by: Zheng HR, et al.
Published: (2022-08-01)

Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study
by: Sun L, et al.
Published: (2023-09-01)

Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study
by: Hu WX, et al.
Published: (2022-04-01)

The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study
by: Hao-Ran Zheng, et al.
Published: (2022-09-01)

Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer
by: Min Yan, et al.
Published: (2024-03-01)

Anlotinib combined with chloroquine induces apoptosis of human non-small cell lung cancer cell line H1299
by: LIU Xi-bang, ZHU Lin-zhi, JIAO De-min, TANG Xia-li, CHEN Jun, HU Xu-gang, CHEN Qing-yong
Published: (2021-07-01)

A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer
by: Wang H, et al.
Published: (2020-05-01)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
by: Jia Li, et al.
Published: (2022-06-01)

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study
by: Likun Chen, et al.
Published: (2023-11-01)

Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study
by: Dou XJ, et al.
Published: (2024-03-01)

Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study
by: Li XY, et al.
Published: (2022-04-01)

Efficacy of Combination of Camrelizumab with Anlotinib as Third-line Therapy for Patients with Advanced Non-small Cell Lung Cancer
by: ZHANG Xiaojuan, et al.
Published: (2023-06-01)

Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study
by: Zou H, et al.
Published: (2022-05-01)

Acceptable Safety of Bevacizumab Therapy in Combination with Chemotherapy in Patients with Advanced Lung Cancer
by: Wei WU, et al.
Published: (2009-03-01)

Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer
by: Ling Chen, et al.
Published: (2023-03-01)

Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance
by: Mingzhao Wang, et al.
Published: (2023-04-01)

Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment
by: Changqing Dong, et al.
Published: (2022-10-01)

Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study)
by: Deyu Li, et al.
Published: (2023-08-01)

Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients
by: Yu Qian, et al.
Published: (2022-12-01)

Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study
by: Jing Yuan, et al.
Published: (2022-06-01)

Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial
by: Shuangshuang Zhao, et al.
Published: (2024-01-01)

Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
by: Lian Yu, et al.
Published: (2023-03-01)

Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells
by: Lijun Liang, et al.
Published: (2019-02-01)

Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial
by: Hui Zhu, MD, et al.
Published: (2022-06-01)

Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer
by: Wenbo Qi, et al.
Published: (2023-01-01)

The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report
by: Wang Deng, et al.
Published: (2024-02-01)

Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)
by: Bo Song, et al.
Published: (2023-09-01)

Survival benefit of anlotinib in T790M‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study
by: Ya Chen, et al.
Published: (2023-08-01)

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study
by: Zhiting Zhao, et al.
Published: (2023-01-01)

Third‐line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double‐blind phase 2 study
by: Ying Cheng, et al.
Published: (2023-06-01)

Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study
by: Bai H, et al.
Published: (2024-02-01)

Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial
by: Kaiyan Chen, et al.
Published: (2023-10-01)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
by: Zhiyong Liu, et al.
Published: (2022-07-01)

Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer
by: JIN Huimin, et al.
Published: (2022-10-01)

A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer
by: Gouling Zhan, et al.
Published: (2023-01-01)

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
by: Zanuso V, et al.
Published: (2023-10-01)

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study
by: Linlin Zhang, et al.
Published: (2023-08-01)

Corrigendum: Successful treatment of a patient with multiple-line relapsed extensive-stage small-cell lung cancer receiving penpulimab combined with anlotinib: A case report
by: Zibo Zhang, et al.
Published: (2022-08-01)